新产业最新股价报60.29元，较前一交易日上涨1.86%。盘中最高触及60.45元，最低下探58.60元，成交 金额达2.61亿元。 新产业主要从事体外诊断产品的研发、生产和销售。公司产品涵盖化学发光免疫分析仪器及配套试剂、 生化分析仪器及配套试剂等。2025年一季度，公司实现营业收入11.25亿元，净利润4.38亿元。 公司公告显示，近日18项化学发光试剂产品获得欧盟IVDR CE认证，有效期至2025年12月14日。截至目 前，公司累计获得211项化学发光试剂和67项生化试剂的IVDR CE认证。 8月20日主力资金净流入187.81万元，近五日主力资金净流出6897.22万元。 风险提示：市场有风险，投资需谨慎。 ...

东方海洋（SZ 002086，收盘价：2.94元）8月20日晚间发布公告称，持有山东东方海洋科技股份有限公 司股份约1.92亿股（占公司总股本比例为9.81%）的大股东深圳前海国元私募证券基金管理有限公司－ 国元价值精选一号私募证券投资基金（简称"国元基金"）计划自2025年9月12日至2025年12月11日以集 中竞价方式和大宗交易方式合计减持公司股份5874万股，不超过上市公司总股本的3%。 2024年1至12月份，东方海洋的营业收入构成为：水产加工业占比47.02%，体外诊断占比23.88%，海水 养殖业占比21.89%，其他业务--租赁及其他占比7.21%。 （文章来源：每日经济新闻） ...

Core Viewpoint - Hangzhou Anxu Biotechnology Co., Ltd. has demonstrated operational resilience amid challenges in the in vitro diagnostics (IVD) industry, including intensified centralized procurement and changes in the international trade environment, by actively adjusting its market strategies [1][3]. Financial Performance - In the first half of 2025, the company reported revenue of 230 million yuan and a net profit of 23.5862 million yuan after deducting non-recurring items [1]. Market Strategy - The company has adopted a "dual-wheel drive" strategy focusing on both international and domestic markets to address uncertainties in overseas markets, leading to a strong adaptability in overall operations despite performance fluctuations [1][3]. - In the domestic market, Anxu Biotechnology successfully obtained multiple medical device registration certificates, including for respiratory virus antigen detection and influenza virus antigen testing kits, targeting essential healthcare needs [1][2]. Business Expansion - The company has developed a dual-track model of "deepening B-end and breaking into C-end" by leveraging the "Anxu Ke" brand to expand into e-commerce, resulting in steady sales growth in home health management products [2]. - Anxu Biotechnology has established a "global network + localized service" system to strengthen its presence in traditional markets such as Europe, Oceania, Asia, and Africa, while also extending into emerging markets to mitigate single-market risks [2]. Diversification - The company is actively expanding into new fields while consolidating its traditional advantages in point-of-care testing (POCT). Its subsidiary, Taimengle, focuses on pet medical testing, developing over a hundred testing solutions for various infectious diseases and health monitoring [2]. - The company has launched the GluMate chronic disease management app, integrating existing POCT products into a comprehensive solution that includes hardware, software, and data services [2]. Industry Outlook - The global IVD market is projected to grow from $109.2 billion in 2024 to $135.1 billion by 2029, with strong growth expected in microfluidic technology and pet medical testing segments [3]. - Despite the overall pressure on the industry in the first half of 2025, the company has shown innovative vitality and resilience through its integrated supply chain, global layout, and diversified business strategies, laying a solid foundation for long-term healthy development [3].

上半年，公司研发投入2.06亿元，完成95项新品上市。截至上半年末，公司累计获得681个产品注册 证，位居IVD（体外诊断）行业前列。 在化学发光平台，公司成功推出基于化学发光高速机FC-9000研发的LA-6000实验室智能化流水线；单 人份化学发光平台在发展中国家中小型实验室快速铺开，截至目前，公司单人份化学发光产品线在全球 范围内获得医疗器械产品注册证150余项。 在免疫荧光层面，推出FS-1000与FS-2000两款干式荧光免疫分析仪，新上市智能干式免疫系统流水线 LA-1000满足快速高效检测需求；免疫胶体金平台，针对《基孔肯雅热防控技术指南（2025版）》发 布，迅速推出胶体金基孔肯雅病毒快筛试剂，助力高效开展精准防控。 病理业务方面，公司自主研发的人类微卫星不稳定性（MSI）检测试剂盒（荧光PCR熔解曲线法）获国 家药监局三类注册证，成为国内首个且唯一获批该方法学检测试剂，实现公司在肿瘤精准检测领域的里 程碑突破。另外公司投资的赛维森科技"宫颈细胞数字病理图像辅助诊断软件"正式获批，这是全国宫颈 细胞学领域首张"AI辅助诊断"三类产品注册证，标志着"数字病理+AI辅诊"模式迈向全新里程 （002 ...

Core Viewpoint - Anxu Bio maintains operational resilience amid challenges in the in vitro diagnostic (IVD) industry, reporting a slight revenue decline but significant profit growth in the first half of 2025 [1][2][3] Group 1: Financial Performance - The company's revenue for the first half of 2025 was 230 million yuan, a year-on-year decrease of 7.42% [1] - The net profit excluding non-recurring items reached 24 million yuan, reflecting a year-on-year increase of 24.89% [1] Group 2: Market Strategy - Anxu Bio has adopted a "dual-wheel drive" strategy focusing on both domestic and international markets to counteract external uncertainties, such as delayed customer orders due to tariffs [1][2] - The company has successfully registered multiple medical device certifications, enhancing its product offerings in critical areas like infectious disease prevention and cardiovascular emergencies [1] Group 3: Business Expansion - The launch of the "Anxu Ke" brand has allowed the company to penetrate the C-end market through e-commerce, establishing a dual-track model of deepening B-end and breaking into C-end markets [2] - Anxu Bio is expanding its presence in the pet medical testing sector through its subsidiary, targeting a market projected to reach 84.1 billion yuan in 2024, growing at 5.6% [2] Group 4: Future Outlook - The global IVD market is expected to grow from 109.2 billion USD in 2024 to 135.1 billion USD by 2029, with strong growth in microfluidic technology and pet medical testing [3] - Anxu Bio's strategy aligns with industry trends by focusing on a diversified product matrix and expanding both domestic and international markets, positioning itself for long-term growth [3]

慢病管理检测领域，公司实施策略调整进一步巩固院内基本盘，化学发光业务通过血栓、细胞因子、高血压等特色项目突 破进院，带动心标、炎症等重点项目的增项实现上量；电化学平台的全自动血气生化分析仪Ucare-6000在国内上市，为等级医 院ICU、呼吸科提供性价比更高的国产解决方案。在国际市场，公司的免疫荧光稳中有升，化学发光、血气品类实现突破，海 外收入稳定增长。 目前，万孚生物已建立覆盖150余个国家与地区的全球服务网络，并在多个国家布局本地化生产基地。今年以来，公司持 续深化全球战略布局，强化重点国家的本地化运营能力。展望未来，公司将以免疫、分子、电化学三大核心技术平台为引擎， 聚焦心脑血管代谢、肿瘤、呼吸道、传染病、妇幼、毒检、糖尿病七大病种，以产品领先为轴心，稳步推进"组合化、国际 化、数智化"三大战略主轴。 毒检领域，上半年公司实现收入1.45亿元，较去年同期增长4.26%。公司将持续深化北美毒检市场研产销一体化布局，推 动注册准入，依托新品优势牵引市场，上半年毒检产品在美国亚马逊平台销售排名第一。 本报讯 （记者王镜茹）8月19日晚，广州万孚生物技术股份有限公司（以下简称"万孚生物"）披露2025年半年 ...

传染病检测领域，公司强化流感检测产品在头部医疗终端的覆盖率，推动肺支、肺衣等呼吸道检测新品 入院，呼吸道三联检产品预计2025年下半年获证，同时在血液、消化道、虫媒传染病领域持续发力。美 国市场，快速推进呼吸道检测新品销售渠道的多元化与全覆盖。发展中国家市场，金标术前血筛等产品 销售有所突破，登革热等老品实现工艺升级。 8月19日晚，万孚生物（300482.SZ）披露半年报。今年上半年，受体外诊断行业竞争加剧与需求承压影 响，公司实现营业收入12.46亿元，归母净利润1.89亿元。面对挑战，公司坚定推进IPD变革以锻造核心 竞争力，始终以产品为根本，持续释放创新活力，夯实免疫领域优势，围绕病种布局构建中长期技术能 力。放眼全球，推动国内国际双循环，通过数智化转型对内深挖潜力要效益，全力推动业务发展。 慢病管理检测领域，公司实施策略调整进一步巩固院内基本盘，化学发光业务通过血栓、细胞因子、高 血压等特色项目突破进院，带动心标、炎症等重点项目的增项上量；电化学平台的全自动血气生化分析 仪Ucare-6000在国内上市，为等级医院ICU、呼吸科提供性价比更高的国产解决方案。在国际市场，公 司的免疫荧光稳中有升，化学 ...

8月19日，燃石医学(BNR)开盘上涨9.35%，截至21:30，报11.121美元/股，成交59.69万美元，总市值 1.20亿美元。 财务数据显示，截至2025年03月31日，燃石医学收入总额1.33亿人民币，同比增长5.94%；归母净利 润-1350.0万人民币，同比增长88.89%。 大事提醒： 本文源自：金融界 作者：行情君 资料显示，燃石医学有限责任公司成立于2014年,公司使命为"用科学守护生命之光", 专注于为肿瘤精准 医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖:1)肿瘤患病人群检测,在 中国拥有领先的市场份额;2)全球抗肿瘤药企的生物标志物和伴随诊断合作;3)多癌种早检。 燃石医学于2018年7月获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒第一证,在体外诊 断领域具有里程碑式意义。位于中国广州的实验室通过广东省临床检验中心颁发的"高通量测序实验 室"技术审核,获得美国CLIA和CAP实验室质量体系资质认证;位于美国加利福尼亚州的实验室也已获得 CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准 医 ...

8月19日晚间，万孚生物（300482）发布2025年半年度业绩报告，公司上半年实现营业收入12.46亿元， 同比下降20.92%；实现净利润1.89亿元，同比下降46.82%。基本每股收益为0.39元。 此外，公司投资的赛维森科技"宫颈细胞数字病理图像辅助诊断软件"正式获批，系全国宫颈细胞学领域 首张"AI辅助诊断"三类产品注册证，标志着"数字病理+AI辅诊"模式迈向全新里程（002219）碑。 报告期内，万孚生物研发投入为20625.02万元，共取得授权发明专利11件，共获得产品注册证合计22 个，其中新增国内产品注册证16个，欧盟CE注册证3个，加拿大MDALL注册证3个。报告期内，公司完 成95项新品上市，其中试剂项目新上市导入93项，仪器上市2款。 报告期内，万孚生物免疫层析分析仪FG-3000完成产品研发，为胶体金平台检测产品的数字化、智能化 提供高效的解决方案；呼吸道三联检产品的临床及注册工作推进顺利，预计2025年下半年获证；除呼吸 道外，公司在血液传染病、消化道传染病、虫媒传染病业务板块持续发力，深耕疾控系统，推 动"POCT+AI"在基层医疗的应用，完成生态破局战。 慢病管理检测领域，万孚 ...

Core Viewpoint - BNR's stock price surged by 30.88% on August 18, reaching $9.79 per share, with a total market capitalization of $105 million [1] Financial Performance - As of March 31, 2025, BNR reported total revenue of 133 million RMB, representing a year-on-year growth of 5.94% [1] - The net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year improvement of 88.89% [1] Company Overview - BNR was established in 2014 with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [1] - The company's business and R&D directions primarily cover: 1) tumor patient population testing, holding a leading market share in China; 2) collaborations with global anti-tumor pharmaceutical companies for biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, BNR received the first certificate for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the in vitro diagnostic field [2] - The laboratory in Guangzhou has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP; the laboratory in California has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]